# NBIX catalysts: NEUROCRINE BIOSCIENCES INC PDUFA dates and FDA events

Canonical: https://sec-api.dev/companies/nbix/catalysts

> NEUROCRINE BIOSCIENCES INC (NBIX) has 30 upcoming catalysts. The next is the osavampator interim data readout, 2027.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day, month only, half-year only, year only, quarter only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Verified answer

### What are the upcoming FDA catalysts for NBIX?

NEUROCRINE BIOSCIENCES INC (NBIX) has 30 upcoming catalysts. The next is the osavampator interim data readout, 2027. SEC Form 10-K: "We have initiated a comprehensive Phase 3 clinical program for osavampator in MDD (with initial topline data expected in 2027), including three acute randomized, double-blind, placebo-controlled studies, a randomized-withdrawal maintenance-of-effect study, and a long-term open-label safety extension, reflecting our confidence in osavampator's potential to elevate the standard of care in MDD." [Calendar and source filings](https://sec-api.dev/companies/nbix/catalysts)

Source: SEC Form 10-K, accession 0000914475-26-000007, https://www.sec.gov/Archives/edgar/data/914475/000091447526000007/nbix-20251231.htm (retrieved 2026-11-12). Last confirmed 2026-02-11. Cite: https://sec-api.dev/companies/nbix/catalysts#answer

## Company

| Field | Value |
| --- | --- |
| Name | NEUROCRINE BIOSCIENCES INC |
| Ticker | NBIX (Nasdaq) |
| SEC CIK | 914475 |
| SIC | 2836 |
| SEC filings | https://sec-api.dev/companies/nbix |

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| April 11, 2017 | [Ingrezza Sprinkle (valbenazine tosylate) FDA approval](https://sec-api.dev/pdufa/valbenazine) | NBIX |  | completed, approved | "NDA209241 ORIG-1 (Type 1 - New Molecular Entity): submission_status AP, submission_status_date 20170411, review_priority PRIORITY; sponsor_name NEUROCRINE; product INGREZZA (VALBENAZINE TOSYLATE)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA209241%22)) |
| April 23, 2021 | [Ingrezza Sprinkle (valbenazine tosylate) label expansion decision](https://sec-api.dev/pdufa/valbenazine) | NBIX |  | completed, approved | "NDA209241 SUPPL-20 (Efficacy): submission_status AP, submission_status_date 20210423, review_priority STANDARD; sponsor_name NEUROCRINE; product INGREZZA (VALBENAZINE TOSYLATE)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA209241%22)) |
| August 18, 2023 | [Ingrezza Sprinkle (valbenazine tosylate) label expansion decision](https://sec-api.dev/pdufa/valbenazine) | NBIX |  | completed, approved | "NDA209241 SUPPL-26 (Efficacy): submission_status AP, submission_status_date 20230818, review_priority STANDARD; sponsor_name NEUROCRINE; product INGREZZA (VALBENAZINE TOSYLATE)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA209241%22)) |
| Apr 2024 | [SAVITRI (savitri) topline data readout](https://sec-api.dev/pdufa/savitri) | NBIX |  | completed, positive | "In April 2024, Neurocrine announced positive topline data for its Phase 2 SAVITRI™ study in adult subjects with MDD." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/914475/000091447525000006/nbix2025127-exhibit991.htm)) |
| Apr 2024 | [Osavampator topline data readout](https://sec-api.dev/pdufa/osavampator) | NBIX | major depressive disorder | completed, positive | "In April 2024, we announced positive top-line data from the Phase 2 SAVITRI™ study of osavampator in adults with major depressive disorder." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/914475/000091447525000037/nbix-20241231.htm)) |
| April 30, 2024 | [Ingrezza Sprinkle (valbenazine tosylate) FDA approval](https://sec-api.dev/pdufa/valbenazine) | NBIX |  | completed, approved | "NDA218390 ORIG-1 (Type 3 - New Dosage Form): submission_status AP, submission_status_date 20240430, review_priority STANDARD; sponsor_name NEUROCRINE; product INGREZZA SPRINKLE (VALBENAZINE TOSYLATE)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA218390%22)) |
| Aug 2024 | [Direclidine topline data readout](https://sec-api.dev/pdufa/direclidine) | NBIX | schizophrenia | completed, positive | "In August 2024, we announced positive top-line data from the Phase 2 clinical study of NBI-1117568 in adults with schizophrenia." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/914475/000091447525000037/nbix-20241231.htm)) |
| December 13, 2024 | [CRENESSITY® (crinecerfont) FDA approval](https://sec-api.dev/pdufa/crinecerfont) | NBIX | To treat classic congenital adrenal hyperplasia Press Release | completed, approved | "Crenessity \| crinecerfont \| 12/13/2024 \| To treat classic congenital adrenal hyperplasia Press ReleaseDrug Trials Snapshot" ([FDA novel drug approvals](https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2024)) |
| 1H 2025 | [Direclidine trial start](https://sec-api.dev/pdufa/direclidine) | NBIX |  | scheduled | "We expect to advance NBI-1117568 into Phase 3 development in the first half of 2025, which would trigger an additional $15.0 million milestone payment to Nxera upon initiation of the Phase 3 study." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/914475/000091447525000037/nbix-20241231.htm)) |
| February 6, 2025 | [NEUROCRINE BIOSCIENCES INC earnings report](https://sec-api.dev/companies/nbix/catalysts) | NBIX |  | completed | "Neurocrine Biosciences Reports Fourth Quarter and Fiscal 2024 Financial Results and Provides Financial Expectations for 2025" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/914475/000091447525000034/q4-2024xearningsrelease.htm)) |
| May 5, 2025 | [NEUROCRINE BIOSCIENCES INC earnings report](https://sec-api.dev/companies/nbix/catalysts) | NBIX |  | completed | "Neurocrine Biosciences Reports First Quarter 2025 Financial Results and Reaffirms 2025 Financial Guidance" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/914475/000091447525000099/q1-2025xearningsrelease.htm)) |
| July 25, 2025 | [NBI-1070770 primary completion](https://sec-api.dev/pdufa/nbi-1070770) | NBIX | Major Depressive Disorder | completed | "NCT06267846 (A Study to Evaluate the Efficacy and Safety of NBI-1070770 in Adults With Major Depressive Disorder): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2025-07-25 (ACTUAL); Lead Sponsor Neurocrine Biosciences." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06267846)) |
| July 30, 2025 | [NEUROCRINE BIOSCIENCES INC earnings report](https://sec-api.dev/companies/nbix/catalysts) | NBIX |  | completed | "Neurocrine Biosciences Reports Second Quarter 2025 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/914475/000091447525000157/q2-2025xearningsrelease.htm)) |
| October 16, 2025 | [Ingrezza Sprinkle (valbenazine tosylate) primary completion](https://sec-api.dev/pdufa/valbenazine) | NBIX | Dyskinesia; Cerebral Palsy | completed | "NCT05206513 (Study to Assess the Efficacy, Safety, and Tolerability of Valbenazine for the Treatment of Dyskinesia Due to Cerebral Palsy): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-10-16 (ACTUAL); Lead Sponsor Neurocrine Biosciences." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05206513)) |
| October 28, 2025 | [NEUROCRINE BIOSCIENCES INC earnings report](https://sec-api.dev/companies/nbix/catalysts) | NBIX |  | completed | "Neurocrine Biosciences Reports Third Quarter 2025 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/914475/000091447525000180/q3-2025xearningsrelease.htm)) |
| November 5, 2025 | [Ingrezza Sprinkle (valbenazine tosylate) primary completion](https://sec-api.dev/pdufa/valbenazine) | NBIX | Chorea, Huntington | withdrawn | "NCT04400331 (Open-Label Rollover Study for Continuing Valbenazine Administration for the Treatment of Chorea Associated With Huntington Disease): Overall Status TERMINATED; Phase PHASE3; Primary Completion 2025-11-05 (ACTUAL); Lead Sponsor Neurocrine Biosciences." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04400331)) |
| November 12, 2025 | [NBI-921352 primary completion](https://sec-api.dev/pdufa/nbi-921352) | NBIX | SCN8A Developmental and Epileptic Encephalopathy Syndrome | withdrawn | "NCT05226780 (Extension Study to Evaluate How Safe and Tolerable NBI-921352 is as an Adjunctive Therapy for Participants With SCN8A-DEE): Overall Status TERMINATED; Phase PHASE2; Primary Completion 2025-11-12 (ACTUAL); Lead Sponsor Neurocrine Biosciences." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05226780)) |
| February 11, 2026 | [NEUROCRINE BIOSCIENCES INC earnings report](https://sec-api.dev/companies/nbix/catalysts) | NBIX |  | completed | "SAN DIEGO, Feb. 11, 2026 - Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced its financial results for the fourth quarter ended December 31, 2025." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/914475/000091447526000006/q4-2025xearningsrelease.htm)) |
| May 5, 2026 | [NEUROCRINE BIOSCIENCES INC earnings report](https://sec-api.dev/companies/nbix/catalysts) | NBIX |  | completed | "SAN DIEGO, May 5, 2026 - Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced its financial results for the first quarter ended March 31, 2026." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/914475/000091447526000025/q1-2026xearningsrelease.htm)) |
| July 30, 2026 | [NEUROCRINE BIOSCIENCES INC earnings report](https://sec-api.dev/companies/nbix/catalysts) | NBIX |  | completed | "SAN DIEGO, July 30, 2026 - Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced its financial results for the second quarter ended June 30, 2026." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/914475/000091447526000035/q2-2026xearningsrelease.htm)) |
| November 2, 2026 | [NEUROCRINE BIOSCIENCES INC earnings report](https://sec-api.dev/companies/nbix/catalysts) | NBIX |  | completed | "SAN DIEGO, Nov. 2, 2026 - Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced its financial results for the third quarter ended September 30, 2026." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/914475/000091447526000053/q3-2026xearningsrelease.htm)) |
| 2027 | [Osavampator interim data readout](https://sec-api.dev/pdufa/osavampator) | NBIX |  | scheduled | "We have initiated a comprehensive Phase 3 clinical program for osavampator in MDD (with initial topline data expected in 2027), including three acute randomized, double-blind, placebo-controlled studies, a randomized-withdrawal maintenance-of-effect study, and a long-term open-label safety extension, reflecting our confidence in osavampator's potential to elevate the standard of care in MDD." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/914475/000091447526000007/nbix-20251231.htm)) |
| 2027 | [Direclidine interim data readout](https://sec-api.dev/pdufa/direclidine) | NBIX |  | scheduled | "We have initiated a comprehensive Phase 3 clinical program for direclidine in schizophrenia (with initial topline data expected in 2027), including studies evaluating efficacy in patients experiencing an acute relapse of schizophrenia and long-term safety." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/914475/000091447526000007/nbix-20251231.htm)) |
| February 2027 | [NBI-1065890 primary completion](https://sec-api.dev/pdufa/nbi-1065890) | NBIX | Tardive Dyskinesia | scheduled | "NCT07365462 (Efficacy, Safety, and Tolerability of NBI-1065890 Versus Placebo in Adults With Tardive Dyskinesia): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-02 (ESTIMATED); Lead Sponsor Neurocrine Biosciences." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07365462)) |
| Feb to May 2027 | [NBI-1065890 topline data readout](https://sec-api.dev/pdufa/nbi-1065890) | NBIX | Tardive Dyskinesia | scheduled | "NCT07365462 (Efficacy, Safety, and Tolerability of NBI-1065890 Versus Placebo in Adults With Tardive Dyskinesia): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-02 (ESTIMATED); Lead Sponsor Neurocrine Biosciences." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07365462)) |
| July 2027 | [NBI-1065845 primary completion](https://sec-api.dev/pdufa/nbi-1065845) | NBIX | Major Depressive Disorder | scheduled | "NCT06786624 (Study to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-07 (ESTIMATED); Lead Sponsor Neurocrine Biosciences." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06786624)) |
| Jul to Oct 2027 | [NBI-1065845 topline data readout](https://sec-api.dev/pdufa/nbi-1065845) | NBIX | Major Depressive Disorder | scheduled | "NCT06786624 (Study to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-07 (ESTIMATED); Lead Sponsor Neurocrine Biosciences." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06786624)) |
| July 2027 | [NBI-1065845 primary completion](https://sec-api.dev/pdufa/nbi-1065845) | NBIX | Major Depressive Disorder | scheduled | "NCT06911112 (NBI-1065845-MDD3025: Study to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-07 (ESTIMATED); Lead Sponsor Neurocrine Biosciences." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06911112)) |
| Jul to Oct 2027 | [NBI-1065845 topline data readout](https://sec-api.dev/pdufa/nbi-1065845) | NBIX | Major Depressive Disorder | scheduled | "NCT06911112 (NBI-1065845-MDD3025: Study to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-07 (ESTIMATED); Lead Sponsor Neurocrine Biosciences." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06911112)) |
| July 2027 | [NBI-1065845 primary completion](https://sec-api.dev/pdufa/nbi-1065845) | NBIX | Major Depressive Disorder | scheduled | "NCT06963021 (NBI-1065845-MDD3026: Study to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-07 (ESTIMATED); Lead Sponsor Neurocrine Biosciences." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06963021)) |
| Jul to Oct 2027 | [NBI-1065845 topline data readout](https://sec-api.dev/pdufa/nbi-1065845) | NBIX | Major Depressive Disorder | scheduled | "NCT06963021 (NBI-1065845-MDD3026: Study to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-07 (ESTIMATED); Lead Sponsor Neurocrine Biosciences." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06963021)) |
| August 2027 | [NBI-1117570 primary completion](https://sec-api.dev/pdufa/nbi-1117570) | NBIX | Schizophrenia | scheduled | "NCT07288333 (Evaluation of NBI-1117570 in Inpatient Adults With Schizophrenia): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-08 (ESTIMATED); Lead Sponsor Neurocrine Biosciences." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07288333)) |
| Aug to Nov 2027 | [NBI-1117570 topline data readout](https://sec-api.dev/pdufa/nbi-1117570) | NBIX | Schizophrenia | scheduled | "NCT07288333 (Evaluation of NBI-1117570 in Inpatient Adults With Schizophrenia): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-08 (ESTIMATED); Lead Sponsor Neurocrine Biosciences." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07288333)) |
| October 2027 | [NBI-1117568 primary completion](https://sec-api.dev/pdufa/nbi-1117568) | NBIX | Schizophrenia | scheduled | "NCT06963034 (NBI-1117568-SCZ3029: Evaluation of NBI-1117568 in Inpatient Adults With Schizophrenia): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-10 (ESTIMATED); Lead Sponsor Neurocrine Biosciences." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06963034)) |
| Oct 2027 to Jan 2028 | [NBI-1117568 topline data readout](https://sec-api.dev/pdufa/nbi-1117568) | NBIX | Schizophrenia | scheduled | "NCT06963034 (NBI-1117568-SCZ3029: Evaluation of NBI-1117568 in Inpatient Adults With Schizophrenia): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-10 (ESTIMATED); Lead Sponsor Neurocrine Biosciences." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06963034)) |
| November 2027 | [NBI-1117568 primary completion](https://sec-api.dev/pdufa/nbi-1117568) | NBIX | Schizophrenia | scheduled | "NCT07105098 (NBI-1117568-SCZ3030: Evaluation of NBI-1117568 in Inpatient Adults With Schizophrenia): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-11 (ESTIMATED); Lead Sponsor Neurocrine Biosciences." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07105098)) |
| Nov 2027 to Feb 2028 | [NBI-1117568 topline data readout](https://sec-api.dev/pdufa/nbi-1117568) | NBIX | Schizophrenia | scheduled | "NCT07105098 (NBI-1117568-SCZ3030: Evaluation of NBI-1117568 in Inpatient Adults With Schizophrenia): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-11 (ESTIMATED); Lead Sponsor Neurocrine Biosciences." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07105098)) |
| February 2028 | [NBI-1117568 primary completion](https://sec-api.dev/pdufa/nbi-1117568) | NBIX | Bipolar I Disorder; Mania | scheduled | "NCT07288320 (An Assessment of Efficacy, Safety, and Pharmacokinetics of NBI-1117568 in Adults With Bipolar I Disorder With Current Mania): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2028-02 (ESTIMATED); Lead Sponsor Neurocrine Biosciences." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07288320)) |
| Feb to May 2028 | [NBI-1117568 topline data readout](https://sec-api.dev/pdufa/nbi-1117568) | NBIX | Bipolar I Disorder; Mania | scheduled | "NCT07288320 (An Assessment of Efficacy, Safety, and Pharmacokinetics of NBI-1117568 in Adults With Bipolar I Disorder With Current Mania): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2028-02 (ESTIMATED); Lead Sponsor Neurocrine Biosciences." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07288320)) |
| Mar to Jun 2028 | [NBIP-01435 topline data readout](https://sec-api.dev/pdufa/nbip-01435) | NBIX | Congenital Adrenal Hyperplasia | scheduled | "NCT07850739 (Efficacy, Safety, Tolerability, and Pharmacokinetics of NBIP-01435 in Adult Participants With Classic Congenital Adrenal Hyperplasia (CAH)): Overall Status NOT_YET_RECRUITING; Phase PHASE2; Primary Completion 2028-03-16 (ESTIMATED); Lead Sponsor Neurocrine Biosciences." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07850739)) |
| March 2028 | [NBIP-01435 primary completion](https://sec-api.dev/pdufa/nbip-01435) | NBIX | Congenital Adrenal Hyperplasia | scheduled | "NCT07850739 (Efficacy, Safety, Tolerability, and Pharmacokinetics of NBIP-01435 in Adult Participants With Classic Congenital Adrenal Hyperplasia (CAH)): Overall Status NOT_YET_RECRUITING; Phase PHASE2; Primary Completion 2028-03-16 (ESTIMATED); Lead Sponsor Neurocrine Biosciences." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07850739)) |
| April 2028 | [Ingrezza Sprinkle (valbenazine tosylate) primary completion](https://sec-api.dev/pdufa/valbenazine) | NBIX | Chorea, Huntington | scheduled | "NCT06312189 (Long-term Study to Evaluate Safety and Tolerability of Valbenazine in Participants With Chorea Associated With Huntington Disease in Canada): Overall Status ENROLLING_BY_INVITATION; Phase PHASE3; Primary Completion 2028-04 (ESTIMATED); Lead Sponsor Neurocrine Biosciences." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06312189)) |
| Apr to Jul 2028 | [Ingrezza Sprinkle (valbenazine tosylate) topline data readout](https://sec-api.dev/pdufa/valbenazine) | NBIX | Chorea, Huntington | scheduled | "NCT06312189 (Long-term Study to Evaluate Safety and Tolerability of Valbenazine in Participants With Chorea Associated With Huntington Disease in Canada): Overall Status ENROLLING_BY_INVITATION; Phase PHASE3; Primary Completion 2028-04 (ESTIMATED); Lead Sponsor Neurocrine Biosciences." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06312189)) |
| May 2028 | [NBI-1117567 primary completion](https://sec-api.dev/pdufa/nbi-1117567) | NBIX | Alzheimer's Disease | scheduled | "NCT07832383 (Evaluation of NBI-1117567 in Participants With Mild to Moderate Alzheimer's Disease (AD) Taking a Background Acetylcholinesterase Inhibitor): Overall Status NOT_YET_RECRUITING; Phase PHASE2; Primary Completion 2028-05 (ESTIMATED); Lead Sponsor Neurocrine Biosciences." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07832383)) |
| May to Aug 2028 | [NBI-1117567 topline data readout](https://sec-api.dev/pdufa/nbi-1117567) | NBIX | Alzheimer's Disease | scheduled | "NCT07832383 (Evaluation of NBI-1117567 in Participants With Mild to Moderate Alzheimer's Disease (AD) Taking a Background Acetylcholinesterase Inhibitor): Overall Status NOT_YET_RECRUITING; Phase PHASE2; Primary Completion 2028-05 (ESTIMATED); Lead Sponsor Neurocrine Biosciences." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07832383)) |
| July 2028 | [Osavampator primary completion](https://sec-api.dev/pdufa/osavampator) | NBIX | Major Depressive Disorder | scheduled | "NCT07196501 (A Study to Evaluate the Maintenance Effect of Osavampator as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-07 (ESTIMATED); Lead Sponsor Neurocrine Biosciences." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07196501)) |
| Jul to Oct 2028 | [Osavampator topline data readout](https://sec-api.dev/pdufa/osavampator) | NBIX | Major Depressive Disorder | scheduled | "NCT07196501 (A Study to Evaluate the Maintenance Effect of Osavampator as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-07 (ESTIMATED); Lead Sponsor Neurocrine Biosciences." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07196501)) |
| May 2029 | [NBI-1065845 primary completion](https://sec-api.dev/pdufa/nbi-1065845) | NBIX | Major Depressive Disorder | scheduled | "NCT06966401 (Long-Term Study to Assess the Safety and Tolerability of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-05 (ESTIMATED); Lead Sponsor Neurocrine Biosciences." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06966401)) |
| May to Aug 2029 | [NBI-1065845 topline data readout](https://sec-api.dev/pdufa/nbi-1065845) | NBIX | Major Depressive Disorder | scheduled | "NCT06966401 (Long-Term Study to Assess the Safety and Tolerability of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-05 (ESTIMATED); Lead Sponsor Neurocrine Biosciences." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06966401)) |
| July 2029 | [NBI-1117568 primary completion](https://sec-api.dev/pdufa/nbi-1117568) | NBIX | Schizophrenia | scheduled | "NCT07227818 (Efficacy of NBI-1117568 in Preventing Relapse in Adults With Schizophrenia): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-07 (ESTIMATED); Lead Sponsor Neurocrine Biosciences." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07227818)) |
| Jul to Oct 2029 | [NBI-1117568 topline data readout](https://sec-api.dev/pdufa/nbi-1117568) | NBIX | Schizophrenia | scheduled | "NCT07227818 (Efficacy of NBI-1117568 in Preventing Relapse in Adults With Schizophrenia): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-07 (ESTIMATED); Lead Sponsor Neurocrine Biosciences." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07227818)) |

## Drugs

- [CRENESSITY® (crinecerfont)](https://sec-api.dev/pdufa/crinecerfont): To treat classic congenital adrenal hyperplasia Press Release
- [Direclidine](https://sec-api.dev/pdufa/direclidine): schizophrenia
- [NBI-1065845](https://sec-api.dev/pdufa/nbi-1065845): Major Depressive Disorder
- [NBI-1065890](https://sec-api.dev/pdufa/nbi-1065890): Tardive Dyskinesia
- [NBI-1070770](https://sec-api.dev/pdufa/nbi-1070770): Major Depressive Disorder
- [NBI-1117567](https://sec-api.dev/pdufa/nbi-1117567): Alzheimer's Disease
- [NBI-1117568](https://sec-api.dev/pdufa/nbi-1117568): Bipolar I Disorder, Schizophrenia
- [NBI-1117570](https://sec-api.dev/pdufa/nbi-1117570): Schizophrenia
- [NBI-921352](https://sec-api.dev/pdufa/nbi-921352): SCN8A Developmental and Epileptic Encephalopathy Syndrome
- [NBIP-01435](https://sec-api.dev/pdufa/nbip-01435): Congenital Adrenal Hyperplasia
- [Osavampator](https://sec-api.dev/pdufa/osavampator): major depressive disorder
- [SAVITRI (savitri)](https://sec-api.dev/pdufa/savitri): 
- [Ingrezza Sprinkle (valbenazine tosylate)](https://sec-api.dev/pdufa/valbenazine): Chorea, Huntington, Dyskinesia

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/companies/nbix/catalysts.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "NBIX catalysts: NEUROCRINE BIOSCIENCES INC PDUFA dates and FDA events." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/companies/nbix/catalysts

```bibtex
@misc{secapidev_companies_nbix_catalysts_20261116,
  title        = {NBIX catalysts: NEUROCRINE BIOSCIENCES INC PDUFA dates and FDA events},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/companies/nbix/catalysts}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_companies_nbix_catalysts_20261116","title":"NBIX catalysts: NEUROCRINE BIOSCIENCES INC PDUFA dates and FDA events","publisher":"sec-api.dev","URL":"https://sec-api.dev/companies/nbix/catalysts","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
